Ascendis Pharma (ASND) Prices 2.5M ADS Offering at $160/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Pre-Open Stock Movers 09/01: (ABVC) (PLAN) (BLCM) Higher; (LCID) (NIO) (ASND) Lower (more...)
September 1, 2021 9:22 AM EDTPre-Open Stock Movers:
ABVC BioPharma, Inc. (NASDAQ: ABVC) 45% HIGHER; filed new PCT (Patent Cooperation Treaty) applications in connection with its medicines that treat major depressive disorder (MDD) and Attention-Deficit Hyperactivity Disorder (ADHD). The two PCT applications describe the treatment methods of oral administrating compositions containing Radix Polygalae (Polygala tenuifolia Willd) extract (PDC-1421). PDC-1421 is the active ingredient for both the companys MDD and ADHD drugs.
Lucid Group (NASDAQ: LCID) 21.8% LOWER; lock-up expires.
Anaplan, Inc. (NYSE:... More
After-Hours Stock Movers 08/31: (PLAN) (PVH) (AMBA) Higher; (CRWD) (ASND) Lower (more...)
August 31, 2021 5:57 PM EDTAfter-Hours Stock Movers:
Anaplan, Inc. (NYSE: PLAN) 14.5% HIGHER; reported Q2 EPS of ($0.09), $0.05 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $144.3 million versus the consensus estimate of $133.99 million. Anaplan, Inc. sees FY2022 revenue of $571.5-573.5 million, versus the consensus of $558 million.
PVH Corp. (NYSE: PVH) 8% HIGHER; reported Q2 EPS of $2.72, $1.52 better than the analyst estimate of $1.20. Revenue for the quarter came in at $2.31 billion versus the consensus estimate of $2.14 billion. PVH... More
Ascendis Pharma (ASND) to Offer $400M in Common Stock
August 31, 2021 4:01 PM EDTAscendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new treatments that make a meaningful difference in patients lives, today announced that it has commenced an underwritten public offering of $400,000,000 of American Depositary Shares (ADSs), each of... More
